CellCentric announces $25m investment from Pfizer
UK-based biotechnology company CellCentric has announced a strategic investment from Pfizer including $25m to finance further development of inobrodib, its first-in-class p300/CBP inhibitor for the treatment of specific cancers.
Pfizer aims to support CellCentric with its own clinical development programmes in multiple myeloma (MM) for 2024, as well as trials in haematological malignancies.
As part of this deal, Astrid Ruefli-Brasse, vice president of Tumour Biology at Pfizer Worldwide Research and Development, will join CellCentric’s scientific advisory board, and Sriram Krishnaswami, vice president and development head of MM at Pfizer Global Product Development will begin acting as an advisor to CellCentric.
This agreement follows the US Food and Drug Administration’s (FDA) granting of Fast Track designation for inobrodib to treat patients with late-stage relapsed refractory multiple myeloma (RRMM), and orphan drug designation for MM treatment.
Will West, CEO and co-founder of CellCentric, commented: “We are delighted to partner with Pfizer to facilitate planning an optimal route to market for inobrodib. This agreement will enable us to build on the strong early clinical data observed to date in RRMM patients. We look forward to making inobrodib available to a broader population of patients who are underserved by existing therapies.”
Astrid Ruefli-Brasse, vice president of Tumour Biology at Pfizer, added: “Today’s agreement with CellCentric will help deliver the next phase of clinical trials for inobrodib, and we look forward to sharing our capabilities and deep understanding of the science behind blood cancers to support the development of this programme. We believe CellCentric’s pioneering work to develop a therapeutic that targets p300/CBP represents a potentially significant new treatment option for patients living with multiple myeloma.”
Exscientia has announced a new collaboration with Merck KGaA, Darmstadt, Germany, with a focus on …
Clinical stage biopharmaceutical company Nuvectis Pharma has announced the initiation of a phase 1a dose …
Valneva and Pfizer have announced positive paediatric and adolescent immunogenicity and safety data for their …